Frequently Asked Questions About Retatrutide
Q: Is Retatrutide approved for use? No. As of June 2026, Retatrutide remains an investigational medication. It has not been approved by the FDA or any other regulatory agency and is only available to participants in clinical trials.
Q: Can I buy Retatrutide or “Retatrutide 10mg” online? No. Any product being sold as Retatrutide outside of clinical trials is unapproved and potentially dangerous. We strongly advise against purchasing such products due to risks of contamination, incorrect dosing, and unknown safety.
Q: What does the “10mg” in the site name refer to? The site focuses on educational information about Retatrutide with particular attention to dosing considerations. While the main Phase 3 trials studied target doses of 4 mg, 9 mg, and 12 mg, some research discussions and titration schedules reference levels around 10 mg as part of individualized or intermediate approaches. There is no large pivotal trial with a primary 10 mg target.
Q: How is Retatrutide given? It is administered as a once-weekly injection under the skin. In the trials, doses were increased gradually every four weeks to help the body adjust.
Q: What were the main side effects in the trials? The most common side effects were gastrointestinal (nausea, vomiting, diarrhea, constipation). These were generally more frequent at higher doses and often improved over time with slow dose increases. Injection site reactions were also reported.
Q: How does Retatrutide differ from semaglutide or tirzepatide? Retatrutide is a triple agonist (GLP-1 + GIP + glucagon), while semaglutide primarily targets GLP-1 and tirzepatide targets GLP-1 + GIP. The added glucagon receptor activity is believed to contribute to increased energy expenditure.
Q: Will Retatrutide be available soon? It is still in Phase 3 trials. Approval timelines are uncertain and depend on the completion of ongoing studies and regulatory review. It is not currently available outside clinical trials.
Q: Can I join a clinical trial for Retatrutide? You can search for active trials on ClinicalTrials.gov using the terms “Retatrutide” or “LY3437943”. Eligibility varies by study. Discuss with your doctor whether any trial might be appropriate for you.
Last reviewed: June 27, 2026
Important: This is educational information only. Retatrutide is investigational and not approved. This is not medical advice. Consult a qualified healthcare professional.